


M. Khasraw1, N. Pavlakis1, S. McCowatt1,2, C. Underhill3, S. Begbie4, P. de Souza4, A. Boyce6, F. Parnis7, V. Lim1, R Harvie1 and G Marx. Multicentre Phase I/II Study of PI-88, a Heparanase Inhibitor in Combination with Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer. Annals of Oncology. Nov 2009

Liangli Zhao1, Brian Y. Lee1, David A. Brown1, Mark P. Molloy1, Gavin M. Marx4, Nick Pavlakis5, Michael J. Boyer6, Martin R. Stockler6, Warren Kaplan7, Samuel N. Breit8, Robert L. Sutherland1, Susan M. Henshall1 and Lisa G. Horvath Identification of Candidate Biomarkers of Therapeutic Response to Docetaxel by Proteomic Profiling. Cancer Research 69, 7696, October 1, 2009


Elizabeth Hovey1, Gavin Marx2, Andrew Kneebone3, Manish Patel1 and Jeremy Shapiro An Australian Clinical Perspective: Management of Hormone Refractory (Androgen-Independent) Prostate Cancer. Asia Pacific Journal of Oncology and Haematology 2009

Rozelle Harvie MSc 1,2, Florian Paturi 1, Robyn Taylor BAppSci 2, Ross Davey PhD1,2, Rick Abraham1, Gavin Marx2, Martin Cullen2, Zoltan Kerestes PhD1,2, and Nick Pavlakis1,2. The predictive role of serum VEGF in an advanced malignant mesothelioma (MM) patient cohort treated with thalidomide alone or combined with cisplatin/gemcitabine. Manuscript in preparation.
